IMPAHCT is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with PAH. The Phase 2b part of the study will assess three doses to establish an optimal dose for the Phase 3 part of the study. The Phase 2b primary endpoint will be the place-bo corrected change in pulmonary vascular resistance (PVR). The Phase 3 primary end-point will be the placebo corrected change in 6-minute walk distance after 24 weeks of treatment. TERMINATED! The while inhaled imatinib was well tolerated, it did not prove to be efficacious.
